Cargando…

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

BACKGROUND: Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmader, Kenneth E, Levin, Myron J, Grupping, Katrijn, Matthews, Sean, Butuk, David, Chen, Michael, Idrissi, Mohamed El, Fissette, Laurence A, Fogarty, Charles, Hartley, Paul, Klein, Nicola P, Nevarez, Max, Uusinarkaus, Kari, Oostvogels, Lidia, Curran, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625580/
https://www.ncbi.nlm.nih.gov/pubmed/30256905
http://dx.doi.org/10.1093/gerona/gly218
_version_ 1783434444065996800
author Schmader, Kenneth E
Levin, Myron J
Grupping, Katrijn
Matthews, Sean
Butuk, David
Chen, Michael
Idrissi, Mohamed El
Fissette, Laurence A
Fogarty, Charles
Hartley, Paul
Klein, Nicola P
Nevarez, Max
Uusinarkaus, Kari
Oostvogels, Lidia
Curran, Desmond
author_facet Schmader, Kenneth E
Levin, Myron J
Grupping, Katrijn
Matthews, Sean
Butuk, David
Chen, Michael
Idrissi, Mohamed El
Fissette, Laurence A
Fogarty, Charles
Hartley, Paul
Klein, Nicola P
Nevarez, Max
Uusinarkaus, Kari
Oostvogels, Lidia
Curran, Desmond
author_sort Schmader, Kenneth E
collection PubMed
description BACKGROUND: Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of participants and implications for caregivers. METHODS: Four hundred and one adults aged 50 years or older received single RZV doses at 0 and 2 months in this open-label, single-arm, multicenter study (NCT02979639). Change in mean SF-36 Physical Functioning score following first-dose administration, quality of life, reactogenicity, safety, productivity loss, and health care resource utilization was assessed. The current analysis was performed post-vaccine dose-1; safety follow-up will continue until 1 year post-dose-2. RESULTS: The most common solicited local symptoms were injection-site pain (77.5%), redness (23.0%), and swelling (13.3%); the most frequent solicited systemic reactions were fatigue (33.5%), headache (28.3%), and myalgia (26.8%). Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed (mean +1.9 points, primary end point), and no overall quality-adjusted-life-year loss was recorded post-dose-1. Five participants reported lost workdays; caregiver workload was not increased. CONCLUSIONS: Overall, the physical functioning and quality of life of older adults were not affected by a first RZV dose. The observed reactogenicity was consistent with previous studies.
format Online
Article
Text
id pubmed-6625580
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-66255802019-07-17 The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial Schmader, Kenneth E Levin, Myron J Grupping, Katrijn Matthews, Sean Butuk, David Chen, Michael Idrissi, Mohamed El Fissette, Laurence A Fogarty, Charles Hartley, Paul Klein, Nicola P Nevarez, Max Uusinarkaus, Kari Oostvogels, Lidia Curran, Desmond J Gerontol A Biol Sci Med Sci The Journal of Gerontology: Translational Section BACKGROUND: Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of participants and implications for caregivers. METHODS: Four hundred and one adults aged 50 years or older received single RZV doses at 0 and 2 months in this open-label, single-arm, multicenter study (NCT02979639). Change in mean SF-36 Physical Functioning score following first-dose administration, quality of life, reactogenicity, safety, productivity loss, and health care resource utilization was assessed. The current analysis was performed post-vaccine dose-1; safety follow-up will continue until 1 year post-dose-2. RESULTS: The most common solicited local symptoms were injection-site pain (77.5%), redness (23.0%), and swelling (13.3%); the most frequent solicited systemic reactions were fatigue (33.5%), headache (28.3%), and myalgia (26.8%). Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed (mean +1.9 points, primary end point), and no overall quality-adjusted-life-year loss was recorded post-dose-1. Five participants reported lost workdays; caregiver workload was not increased. CONCLUSIONS: Overall, the physical functioning and quality of life of older adults were not affected by a first RZV dose. The observed reactogenicity was consistent with previous studies. Oxford University Press 2019-07 2018-09-25 /pmc/articles/PMC6625580/ /pubmed/30256905 http://dx.doi.org/10.1093/gerona/gly218 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of The Gerontological Society of America. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle The Journal of Gerontology: Translational Section
Schmader, Kenneth E
Levin, Myron J
Grupping, Katrijn
Matthews, Sean
Butuk, David
Chen, Michael
Idrissi, Mohamed El
Fissette, Laurence A
Fogarty, Charles
Hartley, Paul
Klein, Nicola P
Nevarez, Max
Uusinarkaus, Kari
Oostvogels, Lidia
Curran, Desmond
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
title The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
title_full The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
title_fullStr The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
title_full_unstemmed The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
title_short The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
title_sort impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: an open-label, phase iii trial
topic The Journal of Gerontology: Translational Section
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625580/
https://www.ncbi.nlm.nih.gov/pubmed/30256905
http://dx.doi.org/10.1093/gerona/gly218
work_keys_str_mv AT schmaderkennethe theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT levinmyronj theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT gruppingkatrijn theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT matthewssean theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT butukdavid theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT chenmichael theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT idrissimohamedel theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT fissettelaurencea theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT fogartycharles theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT hartleypaul theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT kleinnicolap theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT nevarezmax theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT uusinarkauskari theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT oostvogelslidia theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT currandesmond theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT schmaderkennethe impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT levinmyronj impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT gruppingkatrijn impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT matthewssean impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT butukdavid impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT chenmichael impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT idrissimohamedel impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT fissettelaurencea impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT fogartycharles impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT hartleypaul impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT kleinnicolap impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT nevarezmax impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT uusinarkauskari impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT oostvogelslidia impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial
AT currandesmond impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial